Ticatu 60 mg (Ticagrelor)

Adult dosage

This medicine should not be used in combination with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). ㆍAcute coronary syndrome: Administer an initial dose of 180mg, followed by 90mg twice daily. Treatment for 12 months is recommended unless discontinuation is clinically necessary. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. ㆍPatients with a history of myocardial infarction (occurring at least 1 year previously) who are at high risk of thrombotic cardiovascular events: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. - Patients who received this medicine 90mg or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with this medicine 60mg. - Treatment with this medicine may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuation of a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). - The safety and efficacy of this medicine were evaluated at 3 years of follow-up. ㆍPatients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. - Refer to the dosage and administration for acute coronary syndrome patients. - Data on the safety and efficacy of treatment for more than 3 years are limited. ㆍPatients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180mg, followed by 90mg twice daily for 30 days. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended for patients with acute ischemic stroke or high-risk transient ischemic attack. Administration This medicine is administered orally and may be taken regardless of meals. ㆍFor patients who have difficulty swallowing tablets, crush this medicine into a fine powder, disperse it in half a glass of water, and drink the mixture. Rinse the glass with another half glass of water and drink it. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the nasogastric tube with water after administration. ㆍWhen switching from another antiplatelet agent to this medicine, start this medicine 24 hours after the last dose of the previous medicine. ㆍIf a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. Patients with renal impairment No dose adjustment is necessary in patients with renal impairment. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. This medicine has not been studied in patients with severe hepatic impairment, and experience with its use in patients with moderate hepatic impairment is limited.

Children's dosage

The safety and efficacy in pediatric patients under 18 years of age have not been established (see Other section).

This medication works by preventing platelets in the blood from sticking together, thereby reducing the formation of clots. Thus, the risk of bleeding may be increased, and it should not be used in patients with active pathological bleeding or a history of intracranial hemorrhage. If surgery is planned, discontinuing this medication at least 5 days prior to the procedure can help reduce the risk of bleeding. If bleeding symptoms occur, it is essential to inform medical personnel immediately, and it is preferable to treat the bleeding without discontinuing the medication if possible. The concentration of this medication in the blood may change when taken with certain drugs, so it should not be taken particularly with strong CYP3A4 inhibitors or inducers. It should be administered with caution in patients at high risk of bleeding or when combined with other medications that may increase bleeding. Side effects such as respiratory distress or bradycardia may occur, and if such symptoms arise, it is important to consult with healthcare professionals. Women who are pregnant or breastfeeding should use this medication with caution, and women of childbearing age should use appropriate contraception. The risk of bleeding may increase with overdose, so the prescribed dosage and frequency must be strictly followed. Dizziness or confusion may occur while taking this medication, so caution is needed while driving or operating machinery. This medication is not recommended for children under 18 years of age, as safety and efficacy have not been established. It is important to regularly monitor kidney function and signs of bleeding during the course of treatment.

• Bleeding
• dyspnea
• hyperuricemia
• gout
• confusion
• dizziness
• syncope
• headache
• intracranial hemorrhage
• conjunctival hemorrhage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to maintain the storage temperature between 1 and 30 degrees Celsius. This will help preserve the effectiveness of the medication over time.

Appearance

Pink, biconvex, round film-coated tablet

Package unit

56 tablets (14 tablets PTP x 4)